Join the Oncology Voice Network. Join for Free
The DARK Side of MSL-ing-What No One Tells YOU
Medical Science Liaison Key Opinion Leaders career journey challenges faced successful networking

The DARK Side of MSL-ing-What No One Tells YOU


Share This Article


Summary

In this episode, Kirsten Gurtowsky shares her experiences and insights as a Medical Science Liaison. She discusses her career journey, highlighting the balance and flexibility required in the MSL role, as well as the challenges faced. Kirsten delves into the importance of building strong relationships with Key Opinion Leaders and offers strategies for successful networking and engagement. She also provides guidance for aspiring MSLs, drawing on her professional experiences. The episode concludes with Kirsten sharing her excitement and goals for the upcoming year, followed by expressions of appreciation.

Kirsten Gurtowsky, Medical Science Liaison with Novartis, discusses the dark side of being an MSL and what you may not be aware of

Kirsten shares….

πŸ‘‰ What she LOVES about being an MSL
πŸ‘‰ What some of the main frustrations are for MSLs
πŸ‘‰ The challenges of travel and uncertainty
πŸ‘‰ The frustrations that come with paperwork and metrics
πŸ‘‰ Her insights and predictions for 2024

Click for Source
Medical Science Liaison, Key Opinion Leaders, career journey, challenges faced, successful networking

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
Social Media Listening Evolved
Partner Avatar MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson

Social Media Listening Evolved

Podcast
Over-Negotiation-How to Botch a Job Offer
Partner Avatar MSL Talk: Tom Caravela

Over-Negotiation-How to Botch a Job Offer

Article
Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval
OVN Avatar Avi Cherla, MSc; Huseyin Naci, MHS, PhD; Aaron S. Kesselheim, MD, JD, MPH; Bishal Gyawali, MD, PhD; Elias Mossialos, MD, PhD

Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval

Podcast
Hiring Managers Beware: Reverse Rejection Explained!
Partner Avatar Michael Pietrack

Hiring Managers Beware: Reverse Rejection Explained!

Article
The Talent Inflection Point in Pharma and Biotech: A Challenge to Companies β€” and a Call to Candidates
OVN Avatar Jamie Riley

The Talent Inflection Point in Pharma and Biotech: A Challenge to Companies β€” and a Call to Candidates

Article
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
OVN Avatar Michael Z. Liao, Dan Lu, Matts KΓ₯gedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li

Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?

Explore OVN